168 related articles for article (PubMed ID: 27015638)
1. Cerebral infarction after intraarterial and intravenous chemoradiotherapy for head and neck cancer: A retrospective analysis using a Japanese inpatient database.
Suzuki S; Yasunaga H; Matsui H; Fushimi K; Saito Y; Yamasoba T
Head Neck; 2016 Sep; 38(9):1354-8. PubMed ID: 27015638
[TBL] [Abstract][Full Text] [Related]
2. Artificial nutrition dependence after cetuximab versus cisplatin combined with radiotherapy for advanced head and neck cancer: A propensity score-matched analysis.
Ishimaru M; Ono S; Suzuki S; Matsui H; Fushimi K; Yasunaga H
Head Neck; 2017 Feb; 39(2):320-325. PubMed ID: 27635865
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.
Woody NM; Ward MC; Koyfman SA; Reddy CA; Geiger J; Joshi N; Burkey B; Scharpf J; Lamarre E; Prendes B; Adelstein DJ
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):784-792. PubMed ID: 28602410
[TBL] [Abstract][Full Text] [Related]
4. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
5. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
Chang PH; Yeh KY; Wang CH; Chen EY; Yang SW; Huang JS; Chou WC; Hsieh JC
Head Neck; 2017 Oct; 39(10):1990-1996. PubMed ID: 28688124
[TBL] [Abstract][Full Text] [Related]
6. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
[TBL] [Abstract][Full Text] [Related]
9. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
10. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
[TBL] [Abstract][Full Text] [Related]
11. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
[TBL] [Abstract][Full Text] [Related]
12. Earlier and more specific detection of persistent neck disease with diffusion-weighted MRI versus subsequent PET/CT after definitive chemoradiation for oropharyngeal squamous cell carcinoma.
Yu Y; Mabray M; Silveira W; Shen PY; Ryan WR; Uzelac A; Yom SS
Head Neck; 2017 Mar; 39(3):432-438. PubMed ID: 27726241
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
[TBL] [Abstract][Full Text] [Related]
14. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
[TBL] [Abstract][Full Text] [Related]
15. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
[TBL] [Abstract][Full Text] [Related]
16. Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis.
Stokes WA; Amini A; Jones BL; McDermott JD; Raben D; Ghosh D; Goddard JA; Bowles DW; Karam SD
Head Neck; 2017 Jun; 39(6):1113-1121. PubMed ID: 28301079
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional retrospective study for the evaluation of ocular function-preservation rates in maxillary sinus squamous cell carcinomas with orbital invasion.
Sakashita T; Hayashi R; Homma A; Matsuura K; Kato K; Kawabata K; Monden N; Hasegawa Y; Onitsuka T; Fujimoto Y; Iwae S; Okami K; Matsuzuka T; Yoshino K; Fujii M
Head Neck; 2015 Apr; 37(4):537-42. PubMed ID: 24715544
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.
Ko HC; Chen S; Wieland AM; Yu M; Baschnagel AM; Hartig GK; Harari PM; Witek ME
Head Neck; 2017 Nov; 39(11):2159-2170. PubMed ID: 28737019
[TBL] [Abstract][Full Text] [Related]
19. Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.
Birkeland AC; Beesley L; Bellile E; Rosko AJ; Hoesli R; Chinn SB; Shuman AG; Prince ME; Wolf GT; Bradford CR; Brenner JC; Spector ME
Head Neck; 2017 Dec; 39(12):2512-2518. PubMed ID: 28963806
[TBL] [Abstract][Full Text] [Related]
20. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
